Publication | Open Access

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

VaccinationVaccine SafetyVaccine DevelopmentAdenoviral VectoredImmunologyVaccine EfficacyNon-inferiority TrialMrna Covid-19 VaccineMedicineCovid-19